TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05900986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LS301-IT 0.025 mg/kg
Description: The dose of LS301-IT planned to be administered to the first cohort of patients is 0.025 mg/kg. Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased (by 50% as necessary). The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LS301-IT 0.05 mg/kg
Description: Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LS301-IT 0.075 mg/kg
Description: Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LS301-IT 0.1 mg/kg
Description: Depending on the results the dose for subsequent cohorts will be increased to 0.05, 0.075, and 0.1 mg/kg; the dose may also be decreased. The optimal dose determined in Periods 1 and 2 will be administered to patients in Period 3.
Study: NCT06565429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-Step Method Intervention
Description: The 5-Step Method (5SM) intervention is delivered through a self-help handbook: There are writing prompts for the affected family member (AFM) in each step. The steps end with a summary, a space to reflect and a statement that the step is complete but can be reviewed as needed. The steps are: 1.Explore how the relative's drug and/or alcohol misuse is affecting the family member, causing stress and strain. 2.Determine the information the AFM needs to understand the situation using evidence-based websites in the handbook. 3.Reflect on coping styles, and which ones might be useful. 4.Determine who is a source of positive social support, and who could be one that the AFM has not used yet. 5.Review steps 1-4 and determine if the AFM is feeling less stress and strain, or if more help is needed and use websites to look for additional help. The activities should take about 1 hour per week.
Study: NCT05876754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib Oral Tablet
Description: Ivosidenib 500 mg
Study: NCT05417438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable device deployment
Description: Participants will receive a Fitbit to be synced with a smartphone app (MyDataHelps). Participants will receive push notifications to complete surveys via the MyDataHelps app. The Fitbit will sync with the app for data collection.
Study: NCT06654011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018
Description: 100 mg, orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 260 mg/m², IV infusion, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: 10 mg/kg, IV infusion, Q3W
Study: NCT06599996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Testing artificial intelligence algorithms for interpreting gestures
Description: The effectiveness of artificial intelligence algorithms for detecting and interpreting body-based gestures by individuals who have motor/visual impairments will be evaluated.
Study: NCT06601413

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: M-TAPA Block
Description: M-TAPA block will administer ultrasound guided (Sonosite, Inc., Bothell, WA, USA) bilaterally by same anesthesiologist (E.E.) who had more than 10 years experience of regional anesthesia, before weaking from general anesthesia after the surgical procedure. A high-frequency (6-13 MHz) linear probe (HFL38) will be used to identify the transversus abdominis, internal oblique, and external oblique muscles on the costochondral angle in the sagittal plane at the 10th costal margin. In the midclavicular line, between the upper fascia of the transversus abdominis muscle and the lower fascia of the costochondral tissue, at the level of the 10th rib, 20 mL of 0.25 percent bupivacaine will be injected (arcus costarum). The same procedure will be followed on the other side.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Trocar site local anesthetic infiltration
Description: At the end of surgery, infiltration analgesia will be applied to all trocar entry sites (4 port entries) by the surgeon with 10 ml of 0.25% bupivacaine (40 mL in total) without waking the patient.
Study: NCT06587802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triprolizumab
Description: At the end of radiotherapy, 240mg of triplizumab was administered intravenously every cycle (21 days)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rodiotherapy
Description: SBRT radiotherapy (radiotherapy dose: 40Gy, 5 times, 8Gy each time, number of metastatic radiotherapy: ≤5)
Study: NCT06595979

Intervention type: DRUG
Intervention: Polymyxin B
Description: Participants in this group will receive polymyxin B administered directly into the brain (intracranial administration) without intravenous (IV) infusion.

Intervention type: DRUG
Intervention: Polymyxin B
Description: Participants in this group will receive polymyxin B administered directly into the brain (intracranial administration) without intravenous (IV) infusion.
Study: NCT06592729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education
Description: intervention group was taken to scenario-based simulat
Study: NCT06590974

Intervention type: DRUG
Intervention: Freeze-dried Human Protein C Concentrate
Description: Freeze-dried Human Protein C Concentrate (TAK-662) intravenous injection
Study: NCT06593158

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent-delivered Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) for CP children at camp with the guidance and supervision of experts.
Description: * The caregivers delivering HABIT-ILE therapy at camp will follow the same principles as the usual HABIT-ILE. The therapy will take place in a rehabilitation center, and caregivers will provide therapy during the sessions, coached by trained supervisors on site~* The intervention day will then take place, lasting for 5 hours with the constant presence of supervisors. This will be divided into two sessions: a 3-hour intervention in the morning followed by a lunch break, and a 2-hour intervention in the afternoon.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent-delivered Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE) for CP children at home with the online guidance and supervision of experts.
Description: * The caregivers delivering HABIT-ILE therapy at home will follow the same principles as the usual HABIT-ILE. The therapy will take place at children's home, caregivers will provide therapy during the sessions, coached by trained supervisors online~* The intervention day will then take place, lasting for 5 hours with the supervisors through online setting. This will be divided into two sessions: a 3-hour intervention in the morning followed by a lunch break, and a 2-hour intervention in the afternoon.
Study: NCT06598098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Modes
Description: Moderate intensity aerobic exercise, moderate intensity resistance exercise, moderate intensity combination exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Modes
Description: Moderate intensity aerobic exercise, moderate intensity resistance exercise, moderate intensity combination exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Modes
Description: Moderate intensity aerobic exercise, moderate intensity resistance exercise, moderate intensity combination exercise
Study: NCT06595654

Intervention type: OTHER
Group type: OTHER
Intervention: repetitive Transcranial Magnetic Stimulation
Description: * Patient is in a chair.~* Hearing protection will be implemented.~* The corresponding targeting method will be implemented.~* The stimulation coil will be set up according to the indications of the targeting method.~* A caregiver is present throughout the session.~* After the session, the patient is re-assessed clinically for possible adverse effects.~* If an adverse reaction is objectified, a doctor on site, is quickly mobilized.

Intervention type: OTHER
Group type: OTHER
Intervention: repetitive Transcranial Magnetic Stimulation
Description: * Patient is in a chair.~* Hearing protection will be implemented.~* The corresponding targeting method will be implemented.~* The stimulation coil will be set up according to the indications of the targeting method.~* A caregiver is present throughout the session.~* After the session, the patient is re-assessed clinically for possible adverse effects.~* If an adverse reaction is objectified, a doctor on site, is quickly mobilized.

Intervention type: OTHER
Group type: OTHER
Intervention: repetitive Transcranial Magnetic Stimulation
Description: * Patient is in a chair.~* Hearing protection will be implemented.~* The corresponding targeting method will be implemented.~* The stimulation coil will be set up according to the indications of the targeting method.~* A caregiver is present throughout the session.~* After the session, the patient is re-assessed clinically for possible adverse effects.~* If an adverse reaction is objectified, a doctor on site, is quickly mobilized.

Intervention type: OTHER
Group type: OTHER
Intervention: repetitive Transcranial Magnetic Stimulation
Description: * Patient is in a chair.~* Hearing protection will be implemented.~* The corresponding targeting method will be implemented.~* The stimulation coil will be set up according to the indications of the targeting method.~* A caregiver is present throughout the session.~* After the session, the patient is re-assessed clinically for possible adverse effects.~* If an adverse reaction is objectified, a doctor on site, is quickly mobilized.
Study: NCT06603194

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bovine or Marine Collagen
Description: Bovine or Marine Collagen

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bovine or Marine Collagen
Description: Bovine or Marine Collagen

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bovine or Marine Collagen
Description: Bovine or Marine Collagen
Study: NCT06598735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-4508
Description: HRS-4508
Study: NCT06594224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Patients were given 800 mg Ibuprofen in 200 cc normal saline intravenously at the time of arrival in the ward.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: Patients received 20 mg nalbuphine in 200 cc normal saline IV at the time of arrival in the ward.
Study: NCT06602323

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: TMLI/Flu/Mel
Description: Targeted total bone marrow and lymphoid irradiation (TMLI) conformal therapy administered in combination with a reduced-intensity regimen based on Fludarabine and Melphalan.
Study: NCT06596083

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: oral supplement containing: 16.4 grams of medium chained triglycerides, 1mM or sucrose octaacetate and water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester supplement
Description: Oral supplement containing: 25 grams of pure (R)-3-hydroxybutyl-(R)-3-hydroxybutyrate ketone monoester drink
Study: NCT06663670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraneural Facilitation Therapy
Description: * The initial hold, known as the facilitation hold, involves placing the contralateral joint in a maximal loose-pack position that will be comfortable for the patient. An illustration of this would be positioning the ankle joint on the contralateral side in full plantar flexion and inversion. Throughout the entire session, this position will be maintained using a stretch strap. It is crucial to emphasize that there is no muscle engagement in the joint where the facilitation takes place, only a slight stretch.~* Once the pressure elevation occurs, the subsequent phase known as the secondary hold will be initiated to direct the augmented flow of epineurial blood toward the transperineurial vessels connecting the epiperineum and the endoneurial capillaries of the target area.~* The final maneuver, the sub hold, leverages Bernoulli's principle to augment blood flow through the ischemic endoneurial capillaries experiencing heightened transmural pressure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve Flossing Technique
Description: Tibial Nerve:~1. Passively flex the hip while dorsiflexing and everting the ankle to create tension; flex the knee to unload, then extend and plantarflex to reload.~2. Flex the hip, extend the knee, and dorsiflex and evert the ankle to induce tension; flex the hip to unload, then extend and plantarflex to reload.~3. Lift the leg, flex the hip, and extend the knee; dorsiflex and evert the ankle to induce tension, then plantarflex to unload.~Common Peroneal Nerve:~1. Passively flex the hip and plantarflex and invert the ankle to induce tension; flex the knee to unload, then extend and dorsiflex to reload.~2. Flex the hip, extend the knee, and plantarflex and invert the ankle to induce tension; flex the hip to unload, then extend and dorsiflex to reload.~3. Lift the leg, flex the hip, and extend the knee; plantarflex and invert the ankle to induce tension, then dorsiflex to unload.
Study: NCT04272242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine (RPT)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine (RPT)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy (ART)
Description: Participants remained on DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. NRTIs were not provided by the study. Arm 1 participants took non-study supply of DTG for morning doses, and study-supplied DTG for evening doses. For Arm 2 participants, DTG was to have come from non-study ARV supply.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy (ART)
Description: Participants remained on DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. NRTIs were not provided by the study. Arm 1 participants took non-study supply of DTG for morning doses, and study-supplied DTG for evening doses. For Arm 2 participants, DTG was to have come from non-study ARV supply.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine (Vitamin B6)
Description: Participants received 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH, based on the current local, national, or international dosing guidelines. Pyridoxine was not provided by the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine (Vitamin B6)
Description: Participants received 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH, based on the current local, national, or international dosing guidelines. Pyridoxine was not provided by the study.
Study: NCT06597929

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-vigorous physical activity
Description: The experimental group will receive usual care plus the MV-ILPA and education program. First, a physiotherapist will conduct a face-to-face session with the patients detailing the health benefits of moderate to vigorous PA and the negative effects of not including it in their daily lives. Patients will receive a booklet with all the key information. Secondly, participants will take the MV-ILPA program. This program consists of completing 4 length-standardised moderate-to-vigorous intense bouts per day (3 minutes each) of activities of daily living (sit-to-stand, going up/down stairs, walking fast indoors, and walking up small slopes) every day for 12 weeks. Once per week for 12 weeks, a physiotherapist will go to the patient\&#39;s home for a face-to-face session or videoconference. This physiotherapist will foster participants' independence and self-management. The PA intensity will be increased weekly by increasing the execution speed and including weights.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-vigorous physical activity
Description: The experimental group will receive usual care plus the MV-ILPA and education program. First, a physiotherapist will conduct a face-to-face session with the patients detailing the health benefits of moderate to vigorous PA and the negative effects of not including it in their daily lives. Patients will receive a booklet with all the key information. Secondly, participants will take the MV-ILPA program. This program consists of completing 4 length-standardised moderate-to-vigorous intense bouts per day (3 minutes each) of activities of daily living (sit-to-stand, going up/down stairs, walking fast indoors, and walking up small slopes) every day for 12 weeks. Once per week for 12 weeks, a physiotherapist will go to the patient\&#39;s home for a face-to-face session or videoconference. This physiotherapist will foster participants' independence and self-management. The PA intensity will be increased weekly by increasing the execution speed and including weights.
Study: NCT06592612

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT and second-line systemic therapy
Description: Patients in the SBRT arm will receive second-line systemic therapy combined with SBRT. The choice and stipulations for second-line systemic therapy drugs are the same as those for the control arm.SBRT will be administered to all oligoprogressive lesions and must begin within 2 weeks after the start of second-line therapy. Systemic therapy will not be paused during SBRT. Patients who do not withdraw from the study will not receive crossover treatment; however, if a patient in the control group withdraws from the study due to tumor progression and is assessed as suitable for SBRT, salvage SBRT will be administered promptly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Second-line systemic therapy
Description: Patients in the control arm will receive second-line systemic therapy. The following stipulations apply to the second-line treatment drugs: for patients who received bevacizumab combined with atezolizumab/sintilimab as the first-line treatment, lenvatinib or regorafenib will be used for second-line treatment; for patients who received lenvatinib with or without PD-1 antibody as the first-line treatment, regorafenib combined with another PD-1 antibody will be used for second-line treatment.
Study: NCT06593340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messenger 1
Description: The first type of messenger (specific details TBD) that will be used to deliver the environmental sampling results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messenger 1
Description: The first type of messenger (specific details TBD) that will be used to deliver the environmental sampling results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messenger 2
Description: The second type of messenger (specific details TBD) that will be used to deliver the environmental sampling results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messenger 2
Description: The second type of messenger (specific details TBD) that will be used to deliver the environmental sampling results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Format 1
Description: The first type of format (specific details TBD) that will be used to deliver the environmental sampling results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Format 1
Description: The first type of format (specific details TBD) that will be used to deliver the environmental sampling results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Format 2
Description: The second type of format (specific details TBD) that will be used to deliver the environmental sampling results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Format 2
Description: The second type of format (specific details TBD) that will be used to deliver the environmental sampling results.
Study: NCT06592365

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GTE
Description: oral administration of GTE tablets once daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration of placebo tablets once daily for 12 weeks
Study: NCT06589219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CMR316
Description: CMR316 administered via nebulization at single or multiple dose(s) assigned by cohort

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CMR316
Description: CMR316 administered via nebulization at single or multiple dose(s) assigned by cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMR316
Description: CMR316 administered via nebulization at single or multiple dose(s) assigned by cohort

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via nebulization at single or multiple dose(s) to match CMR316 administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via nebulization at single or multiple dose(s) to match CMR316 administration
Study: NCT06602557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin
Description: Patients included in the inhaled amikacin group will receive inhaled antibiotic therapy by nebulization of amikacin at a dose of 25 mg/kg in 1 daily dose (+/- 3 hours apart), within 6 hours of randomization and for a total duration of 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients included in the standard of care group will not receive any nebulization. They will receive Standard care alone.